DE122006000012I1 - Lhrh antagonistische Peptide - Google Patents

Lhrh antagonistische Peptide

Info

Publication number
DE122006000012I1
DE122006000012I1 DE1996623254 DE69623254C DE122006000012I1 DE 122006000012 I1 DE122006000012 I1 DE 122006000012I1 DE 1996623254 DE1996623254 DE 1996623254 DE 69623254 C DE69623254 C DE 69623254C DE 122006000012 I1 DE122006000012 I1 DE 122006000012I1
Authority
DE
Germany
Prior art keywords
moiety
longer
peptide compound
antagonistic peptides
lhrh
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
DE1996623254
Other languages
English (en)
Other versions
DE69623254T2 (de
DE69623254D1 (de
Inventor
W Roeske
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Indiana University Research and Technology Corp
Original Assignee
Indiana University Research and Technology Corp
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Indiana University Research and Technology Corp filed Critical Indiana University Research and Technology Corp
Publication of DE122006000012I1 publication Critical patent/DE122006000012I1/de
Pending legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K7/00—Peptides having 5 to 20 amino acids in a fully defined sequence; Derivatives thereof
    • C07K7/04—Linear peptides containing only normal peptide links
    • C07K7/23—Luteinising hormone-releasing hormone [LHRH]; Related peptides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/08—Drugs for disorders of the urinary system of the prostate
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A61P15/16—Masculine contraceptives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A61P15/18—Feminine contraceptives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/04—Immunostimulants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A61P5/02—Drugs for disorders of the endocrine system of the hypothalamic hormones, e.g. TRH, GnRH, CRH, GRH, somatostatin
    • A61P5/04—Drugs for disorders of the endocrine system of the hypothalamic hormones, e.g. TRH, GnRH, CRH, GRH, somatostatin for decreasing, blocking or antagonising the activity of the hypothalamic hormones
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y10—TECHNICAL SUBJECTS COVERED BY FORMER USPC
    • Y10S—TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y10S930/00—Peptide or protein sequence
    • Y10S930/01—Peptide or protein sequence
    • Y10S930/13—Luteinizing hormone-releasing hormone; related peptides
DE1996623254 1995-06-07 1996-06-07 Lhrh antagonistische Peptide Pending DE122006000012I1 (de)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US08/480,494 US5843901A (en) 1995-06-07 1995-06-07 LHRH antagonist peptides
PCT/US1996/009852 WO1996040757A2 (en) 1995-06-07 1996-06-07 Lhrh antagonist peptides

Publications (1)

Publication Number Publication Date
DE122006000012I1 true DE122006000012I1 (de) 2006-06-29

Family

ID=23908180

Family Applications (4)

Application Number Title Priority Date Filing Date
DE69535963T Expired - Lifetime DE69535963D1 (de) 1995-06-07 1996-06-07 LHRH antagonistische Peptide
DE122006000012C Active DE122006000012I2 (de) 1995-06-07 1996-06-07 Lhrh antagonistische peptide
DE69623254T Expired - Lifetime DE69623254T2 (de) 1995-06-07 1996-06-07 Lhrh antagonistische peptide
DE1996623254 Pending DE122006000012I1 (de) 1995-06-07 1996-06-07 Lhrh antagonistische Peptide

Family Applications Before (3)

Application Number Title Priority Date Filing Date
DE69535963T Expired - Lifetime DE69535963D1 (de) 1995-06-07 1996-06-07 LHRH antagonistische Peptide
DE122006000012C Active DE122006000012I2 (de) 1995-06-07 1996-06-07 Lhrh antagonistische peptide
DE69623254T Expired - Lifetime DE69623254T2 (de) 1995-06-07 1996-06-07 Lhrh antagonistische peptide

Country Status (13)

Country Link
US (4) US5843901A (de)
EP (2) EP1188768B1 (de)
JP (3) JP4164125B2 (de)
AT (2) ATE432941T1 (de)
AU (1) AU715399B2 (de)
CA (1) CA2219460C (de)
DE (4) DE69535963D1 (de)
DK (2) DK0794961T3 (de)
ES (2) ES2326861T3 (de)
HK (1) HK1045161B (de)
LU (2) LU91225I2 (de)
PT (2) PT1188768E (de)
WO (1) WO1996040757A2 (de)

Families Citing this family (109)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
IL117175A (en) 1995-02-20 2005-11-20 Sankyo Co Osteoclastogenesis inhibitory factor protein
US5843901A (en) * 1995-06-07 1998-12-01 Advanced Research & Technology Institute LHRH antagonist peptides
US5780435A (en) 1995-12-15 1998-07-14 Praecis Pharmaceuticals Incorporated Methods for treating prostate cancer with LHRH-R antagonists
US5968895A (en) 1996-12-11 1999-10-19 Praecis Pharmaceuticals, Inc. Pharmaceutical formulations for sustained drug delivery
AU713471C (en) 1996-12-23 2002-04-18 Immunex Corporation Ligand for receptor activator of NF-kappa B, ligand is member of TNF superfamily
US5925730A (en) * 1997-04-11 1999-07-20 Ferring Bv GnRH antagonists
DE69834699T3 (de) * 1997-04-15 2013-11-14 Daiichi Sankyo Co., Ltd. Neues protein und verfahren zu dessen herstellung
US6316408B1 (en) * 1997-04-16 2001-11-13 Amgen Inc. Methods of use for osetoprotegerin binding protein receptors
TR199902512T2 (xx) 1997-04-16 2000-06-21 Amgen Inc. Osteoprotegerin ba�lay�c� proteinler ve resept�rler.
US6217844B1 (en) * 1998-04-27 2001-04-17 Praecis Pharmaceuticals, Inc. Methods for detecting lesions in dense breast tissue using LHRH antagonists
WO1999055358A1 (en) * 1998-04-27 1999-11-04 Praecis Pharmaceuticals Incorporated Methods for treating hot flashes and gynaecomastia
US6191115B1 (en) * 1998-08-12 2001-02-20 Abbott Laboratories C-terminus modified heptapeptide LHRH analogs
US6455499B1 (en) * 1999-02-23 2002-09-24 Indiana University Foundation Methods for treating disorders associated with LHRH activity
US6703367B1 (en) * 1999-04-27 2004-03-09 Praecis Pharmaceuticals Inc. Methods for treating hot flashes and gynaecomastia
JP2003506411A (ja) * 1999-08-09 2003-02-18 トリペップ アクチ ボラゲット タンパク質重合阻害剤および使用方法
ES2287028T3 (es) * 1999-09-03 2007-12-16 Amgen Inc. Composiciones y metodos para la prevencion o el tratamiento de cancer y de la perdida osea asociada con el cancer.
US20030103978A1 (en) 2000-02-23 2003-06-05 Amgen Inc. Selective binding agents of osteoprotegerin binding protein
US7109171B2 (en) 2000-02-28 2006-09-19 Praecis Pharmaceuticals Inc. Methods for treating FSH related conditions with GnRH antagonists
EP1298142A4 (de) * 2000-06-30 2005-12-21 Suntory Ltd GONADOTROPIN-FREISETZENDES HORMON, VORLäUFERPEPTIDE UND DAFüR KODIERENDE GENE
US6598784B2 (en) * 2000-12-20 2003-07-29 Meadwestvaco Packaging Syatens, Llc Beverage carton with strap type carrying handle
AU2002235348A1 (en) * 2001-01-17 2002-07-30 Praecis Pharmaceuticals Inc. Methods for treating hormone associated conditions using a combination of lhrh antagonists and specific estrogen receptor modulators
AU2002250968C1 (en) * 2001-02-19 2018-01-04 Novartis Ag Cancer treatment
NZ529145A (en) 2001-05-16 2005-07-29 Novartis Ag Combination comprising N-{5-[4-(4-methyl-piperazino-methyl)-benzoylamido]-2-methylphenyl}-4-(3-pyridyl)- 2pyrimidine-amine and a chemotherapeutic agent
EP1408876A4 (de) 2001-06-22 2004-09-22 Durect Corp Koaxiale implantate nullter ordnung mit verlängerter freisetzung
DE60235989D1 (de) 2001-06-26 2010-05-27 Amgen Fremont Inc Antikörper gegen opgl
US6593455B2 (en) * 2001-08-24 2003-07-15 Tripep Ab Tripeptide amides that block viral infectivity and methods of use thereof
GB0128510D0 (en) * 2001-11-28 2002-01-23 Novartis Ag Organic compounds
US7718776B2 (en) 2002-04-05 2010-05-18 Amgen Inc. Human anti-OPGL neutralizing antibodies as selective OPGL pathway inhibitors
EP1955696B1 (de) 2002-05-16 2014-05-28 Novartis AG Verwendung vom EDG-Rezeptorbindemittel FTY720 bei Krebs
US6861236B2 (en) 2002-05-24 2005-03-01 Applied Nanosystems B.V. Export and modification of (poly)peptides in the lantibiotic way
NZ564694A (en) 2003-04-22 2009-11-27 Sod Conseils Rech Applic Peptide vectors
GB0320806D0 (en) 2003-09-05 2003-10-08 Astrazeneca Ab Therapeutic treatment
JP4407322B2 (ja) * 2004-03-09 2010-02-03 味の素株式会社 ペプチドの製造方法
PL2253614T3 (pl) 2004-04-07 2013-03-29 Novartis Ag Inhibitory IAP
GB0512324D0 (en) 2005-06-16 2005-07-27 Novartis Ag Organic compounds
EP1845973B1 (de) 2005-01-21 2015-08-12 Astex Therapeutics Limited Pharmazeutische verbindungen
GB0510390D0 (en) 2005-05-20 2005-06-29 Novartis Ag Organic compounds
BRPI0616755A2 (pt) 2005-09-27 2011-06-28 Novartis Ag compostos de carboxiamina e métodos de uso dos mesmos
US7942867B2 (en) * 2005-11-09 2011-05-17 The Invention Science Fund I, Llc Remotely controlled substance delivery device
GB0605120D0 (en) 2006-03-14 2006-04-26 Novartis Ag Organic Compounds
KR20090007635A (ko) 2006-05-09 2009-01-19 노파르티스 아게 철 킬레이터 및 항-신생물 약제를 포함하는 조합물 및 그의용도
JP2010504933A (ja) 2006-09-29 2010-02-18 ノバルティス アーゲー Ｐｉ３ｋ脂質キナーゼ阻害剤としてのピラゾロピリミジン
EP2073807A1 (de) 2006-10-12 2009-07-01 Astex Therapeutics Limited Pharmazeutische kombinationen
US8916552B2 (en) 2006-10-12 2014-12-23 Astex Therapeutics Limited Pharmaceutical combinations
EP2359818A1 (de) 2007-02-15 2011-08-24 Novartis AG Kombinationen von LB589 mit HSP 90 Inhibitoren zur Krebsbehandlung
MX2010010525A (es) 2008-03-24 2010-10-25 Novartis Ag Inhibidores de metaloproteasa de matriz basados en aril-sulfonamida.
NZ588069A (en) 2008-03-26 2012-06-29 Novartis Ag Hydroxamate-based inhibitors of deacetylases b
DK2370076T3 (en) * 2008-11-28 2017-04-03 Novartis Ag Pharmaceutical combination comprising an Hsp 90 inhibitor and an mTOR inhibitor
WO2010083617A1 (en) 2009-01-21 2010-07-29 Oncalis Ag Pyrazolopyrimidines as protein kinase inhibitors
US20120053122A1 (en) 2009-01-22 2012-03-01 Maatschap Interne Geneeskunde Rijnstate Method for the prophylaxis or treatment of flushing
EP2391366B1 (de) 2009-01-29 2012-11-28 Novartis AG Substituierte benzimidazole zur behandlung von astrozytomen
SI2445903T1 (sl) 2009-06-26 2014-07-31 Novartis Ag 1,3-disubstituirani imidazolidin-2-onski derivati kot inhibitorji CYP 17
US8389526B2 (en) 2009-08-07 2013-03-05 Novartis Ag 3-heteroarylmethyl-imidazo[1,2-b]pyridazin-6-yl derivatives
MX2012001838A (es) 2009-08-12 2012-02-29 Novartis Ag Compuestos de hidrazona heterociclico y sus usos para tratar cancer e inflamacion.
KR20120089463A (ko) 2009-08-20 2012-08-10 노파르티스 아게 헤테로시클릭 옥심 화합물
BR112012008075A2 (pt) 2009-08-26 2016-03-01 Novartis Ag compostos de heteroarila tetrassubstituídos e seu uso como moduladores de mdm2 e/ou mdm4
CA2773661A1 (en) 2009-09-10 2011-03-17 Novartis Ag Ether derivatives of bicyclic heteroaryls
MY156209A (en) 2009-11-04 2016-01-29 Novartis Ag Heterocyclic sulfonamide derivatives useful mek inhibitors
US20120289501A1 (en) 2009-11-25 2012-11-15 Novartis Ag Benzene-fused 6-membered oxygen-containing heterocyclic derivatives of bicyclic heteroaryls
CA2781218A1 (en) 2009-12-08 2011-06-16 Novartis Ag Heterocyclic sulfonamide derivatives
US8440693B2 (en) 2009-12-22 2013-05-14 Novartis Ag Substituted isoquinolinones and quinazolinones
CU24130B1 (es) 2009-12-22 2015-09-29 Novartis Ag Isoquinolinonas y quinazolinonas sustituidas
UA112517C2 (uk) 2010-07-06 2016-09-26 Новартіс Аг Тетрагідропіридопіримідинові похідні
SG177783A1 (en) 2010-07-09 2012-02-28 Smart Communications Inc Content provision system and method
US8946260B2 (en) 2010-09-16 2015-02-03 Novartis Ag 17α-hydroxylase/C17,20-lyase inhibitors
JP2014505088A (ja) 2011-02-10 2014-02-27 ノバルティス アーゲー Ｃ−ＭＥＴチロシンキナーゼ阻害剤としての［１，２，４］トリアゾロ［４，３−ｂ］ピリダジン化合物
CN103492390A (zh) 2011-03-08 2014-01-01 诺瓦提斯公司 氟苯基双环杂芳基化合物
CN103649073B (zh) 2011-04-28 2016-04-13 诺瓦提斯公司 17α-羟化酶/C17,20-裂合酶抑制剂
IN2014DN00123A (de) 2011-06-09 2015-05-22 Novartis Ag
US8859535B2 (en) 2011-06-20 2014-10-14 Novartis Ag Hydroxy substituted isoquinolinone derivatives
WO2012175487A1 (en) 2011-06-20 2012-12-27 Novartis Ag Cyclohexyl isoquinolinone compounds
KR20140025530A (ko) 2011-06-27 2014-03-04 노파르티스 아게 테트라히드로-피리도-피리미딘 유도체의 고체 형태 및 염
BR112014006223A8 (pt) 2011-09-15 2018-01-09 Novartis Ag 3-(quinolin-6-iltio)-[1,2,4-triazol[4,3-a] piradinas 6-substituídas, seus usos, composições farmacêuticas, e combinação
JP5992054B2 (ja) 2011-11-29 2016-09-14 ノバルティス アーゲー ピラゾロピロリジン化合物
WO2013093850A1 (en) 2011-12-22 2013-06-27 Novartis Ag Quinoline derivatives
EA025322B1 (ru) 2011-12-22 2016-12-30 Новартис Аг Производные дигидробензооксазина и дигидропиридооксазина
JP2015503515A (ja) 2011-12-23 2015-02-02 ノバルティス アーゲー Ｂｃｌ２と結合相手の相互作用を阻害するための化合物および組成物
CN104125953A (zh) 2011-12-23 2014-10-29 诺华股份有限公司 用于抑制bcl2与结合配偶体相互作用的化合物
WO2013096055A1 (en) 2011-12-23 2013-06-27 Novartis Ag Compounds for inhibiting the interaction of bcl2 with binding partners
EP2794591A1 (de) 2011-12-23 2014-10-29 Novartis AG Verbindungen zur hemmung der interaktion von bcl2 mit bindungspartnern
CA2859873A1 (en) 2011-12-23 2013-06-27 Novartis Ag Compounds for inhibiting the interaction of bcl2 with binding partners
US8815926B2 (en) 2012-01-26 2014-08-26 Novartis Ag Substituted pyrrolo[3,4-D]imidazoles for the treatment of MDM2/4 mediated diseases
US9365576B2 (en) 2012-05-24 2016-06-14 Novartis Ag Pyrrolopyrrolidinone compounds
EP2861256B1 (de) 2012-06-15 2019-10-23 The Brigham and Women's Hospital, Inc. Zusammensetzungen zur behandlung von krebs und verfahren zur herstellung davon
PE20150998A1 (es) 2012-10-02 2015-06-29 Epitherapeutics Aps Inhibidores de histona demetilasas
TW201422625A (zh) 2012-11-26 2014-06-16 Novartis Ag 二氫－吡啶并－□衍生物之固體形式
US9556180B2 (en) 2013-01-22 2017-01-31 Novartis Ag Pyrazolo[3,4-d]pyrimidinone compounds as inhibitors of the P53/MDM2 interaction
EP2948451B1 (de) 2013-01-22 2017-07-12 Novartis AG Substituierte purinonverbindungen
WO2014128612A1 (en) 2013-02-20 2014-08-28 Novartis Ag Quinazolin-4-one derivatives
PL2961736T3 (pl) 2013-02-27 2018-08-31 Gilead Sciences, Inc. Inhibitory demetylaz histonowych
US20150018376A1 (en) 2013-05-17 2015-01-15 Novartis Ag Pyrimidin-4-yl)oxy)-1h-indole-1-carboxamide derivatives and use thereof
UY35675A (es) 2013-07-24 2015-02-27 Novartis Ag Derivados sustituidos de quinazolin-4-ona
US9227969B2 (en) 2013-08-14 2016-01-05 Novartis Ag Compounds and compositions as inhibitors of MEK
WO2015022664A1 (en) 2013-08-14 2015-02-19 Novartis Ag Compounds and compositions as inhibitors of mek
WO2015022663A1 (en) 2013-08-14 2015-02-19 Novartis Ag Compounds and compositions as inhibitors of mek
US9657007B2 (en) 2013-09-22 2017-05-23 Calitor Sciences, Llc Substituted aminopyrimidine compounds and methods of use
WO2015107461A1 (en) 2014-01-15 2015-07-23 Novartis Ag Pharmaceutical combinations
JP6517319B2 (ja) 2014-03-28 2019-05-22 キャリター・サイエンシーズ・リミテッド・ライアビリティ・カンパニーＣａｌｉｔｏｒ Ｓｃｉｅｎｃｅｓ， Ｌｌｃ 置換されたヘテロアリール化合物および使用方法
WO2015153498A1 (en) 2014-03-31 2015-10-08 Epitherapeutics, Aps Inhibitors of histone demethylases
BR112016022499A2 (pt) 2014-04-03 2017-08-15 Invictus Oncology Pvt Ltd Produtos terapêuticos combinatórios supramoleculares
AU2015306662A1 (en) 2014-08-27 2017-03-09 Gilead Sciences, Inc. Compounds and methods for inhibiting histone demethylases
WO2016154120A1 (en) 2015-03-20 2016-09-29 The Regents Of The University Of California Polypeptides, peptides, and proteins functionalized by alkylation of thioether groups via ring-opening reactions
EP3124495A1 (de) 2015-07-31 2017-02-01 Centre National de la Recherche Scientifique (C.N.R.S.) Derivate von elastin-ähnlichen polypeptiden und verwendungen davon
EP3347097B1 (de) 2015-09-11 2021-02-24 Sunshine Lake Pharma Co., Ltd. Substituierte aminopyrimidin-derivate als modulatoren der kinasen jak, flt3 und aurora
US11732008B2 (en) 2016-04-27 2023-08-22 The Regents Of The University Of California Preparation of functional homocysteine residues in polypeptides and peptides
EP3710006A4 (de) 2017-11-19 2021-09-01 Sunshine Lake Pharma Co., Ltd. Substituierte heteroarylverbindungen und verfahren zur verwendung
US11602534B2 (en) 2017-12-21 2023-03-14 Hefei Institutes Of Physical Science, Chinese Academy Of Sciences Pyrimidine derivative kinase inhibitors
AU2019209960B2 (en) 2018-01-20 2023-11-23 Sunshine Lake Pharma Co., Ltd. Substituted aminopyrimidine compounds and methods of use
CN109926430A (zh) * 2018-11-19 2019-06-25 云南省环境科学研究院(中国昆明高原湖泊国际研究中心) 一种重金属废渣还原造锍熔炼处置的方法

Family Cites Families (76)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3787385A (en) * 1971-05-17 1974-01-22 K Folkers Synthetically produced tetrapeptide having the activity of the luteinizing hormone releasing hormone
US3974135A (en) * 1971-06-24 1976-08-10 Karl Folkers Synthetic decapeptide having the activity of the luteinizing hormone releasing hormone and method for producing the same
US3953416A (en) * 1971-12-20 1976-04-27 Karl Folkers Synthetic decapeptide having the activity of the luteinizing hormone releasing hormone and method for manufacturing the same
GB1542703A (en) 1975-10-29 1979-03-21 Parke Davis & Co Nonapeptides and methods for their production
BE847761A (fr) * 1975-10-29 1977-02-14 Nouveaux octapeptides et procedes pour les produire,
DE2617646C2 (de) * 1976-04-22 1986-07-31 Hoechst Ag, 6230 Frankfurt Nonapeptid-amide und Decapeptid-amide mit Gonadoliberin-Wirkung, Verfahren zu ihrer Herstellung und diese Verbindungen enthaltende pharmazeutische Präparate
US4215038A (en) * 1978-10-16 1980-07-29 The Salk Institute For Biological Studies Peptides which inhibit gonadal function
US4307083A (en) * 1978-10-16 1981-12-22 The Salk Institute For Biological Studies LRF Antagonists
US4244946A (en) * 1979-06-11 1981-01-13 The Salk Institute For Biological Studies Water-soluble peptides affecting gonadal function
US4409208A (en) * 1980-04-15 1983-10-11 The Salk Institute For Biological Studies GnRH antagonists
US4292313A (en) * 1980-04-15 1981-09-29 The Salk Institute For Biological Studies LRF Antagonists
US4377574A (en) * 1980-06-26 1983-03-22 The Salk Institute For Biological Studies Contraceptive treatment of male mammals
US4386074A (en) * 1980-08-29 1983-05-31 The Salk Institute For Biological Studies LRF Antagonists
US4419347A (en) * 1980-10-06 1983-12-06 Syntex (U.S.A.) Inc. Nonapeptide and decapeptide analogs of LHRH, useful as LHRH antagonists
US4341767A (en) * 1980-10-06 1982-07-27 Syntex Inc. Nonapeptide and decapeptide analogs of LHRH, useful as LHRH antagonists
US4489061A (en) * 1981-06-12 1984-12-18 The Salk Institute For Biological Studies Treatment of male mammals
US4481190A (en) * 1982-12-21 1984-11-06 Syntex (U.S.A.) Inc. Nonapeptide and decapeptide analogs of LHRH useful as LHRH antagonists
US4667014A (en) * 1983-03-07 1987-05-19 Syntex (U.S.A.) Inc. Nonapeptide and decapeptide analogs of LHRH, useful as LHRH antagonists
US4581169A (en) * 1982-12-21 1986-04-08 Syntex (U.S.A.) Inc. Nona-peptide and deca-peptide analogs of LHRH, useful as LHRH antagonists
US4444759A (en) * 1982-07-26 1984-04-24 The Salk Institute For Biological Studies GnRH Antagonists II
US4619914A (en) * 1983-03-10 1986-10-28 The Salk Institute For Biological Studies GNRH antagonists IIIB
US4504414A (en) * 1983-03-28 1985-03-12 Board Of Regents, The University Of Texas System Synthetic pyridyl-alanyl decapeptides having antiovulatory activity
DE3467173D1 (en) * 1983-08-16 1987-12-10 Akzo Nv Lh- rh antagonists
US4547370A (en) * 1983-11-29 1985-10-15 The Salk Institute For Biological Studies GnRH Antagonists
US4569927A (en) * 1984-02-23 1986-02-11 The Salk Institute For Biological Studies GnRH Antagonists IV
US4652550A (en) * 1984-05-21 1987-03-24 The Salk Institute For Biological Studies GnRH antagonists VII
US4647653A (en) * 1984-08-23 1987-03-03 Tulane Educational Fund Therapeutic peptides
US4565804A (en) * 1984-09-07 1986-01-21 The Salk Institute For Biological Studies GnRH Antagonists VI
US4690916A (en) * 1984-11-13 1987-09-01 Syntex (U.S.A.) Inc. Nona and decapeptide analogs of LHRH useful as LHRH antagonists
US4740500A (en) * 1985-01-31 1988-04-26 The Salk Institute For Biological Studies GnRH antagonists VIII
US4659691A (en) * 1985-02-08 1987-04-21 Merck & Co., Inc. Novel cyclic Hexapeptide LHRH antagonists
US4677193A (en) * 1985-02-22 1987-06-30 The Salk Institute For Biological Studies Peptides containing an aliphatic-aromatic ketone side chain
US5003011A (en) * 1985-04-09 1991-03-26 The Administrators Of The Tulane Educational Fund Therapeutic decapeptides
US5073624A (en) * 1985-04-09 1991-12-17 Administrators Of The Tulane Educational Fund Therapeutic decapeptides
US4866160A (en) * 1985-04-09 1989-09-12 The Administrators Of The Tulane Educational Fund Therapeutic decapeptides
US4656247A (en) * 1985-04-26 1987-04-07 Board Of Regents, The University Of Texas System Effective hormonal peptides: D-3-QA1 6-LHRH
US4642332A (en) * 1985-04-26 1987-02-10 The Board Of Regents, The University Of Texas System Effective hormonal peptides: D-3-Pal6 -LHRH
US4661472A (en) * 1985-05-09 1987-04-28 The Salk Institute For Biological Studies GnRH antagonists IX
US4721775A (en) * 1985-08-26 1988-01-26 Board Of Regents, The University Of Texas System Effective peptides related to the luteinizing hormone releasing hormone from L-amino acids
US4705778A (en) * 1985-10-22 1987-11-10 Sri International Orally active LHRH analogs
US5182205A (en) * 1986-11-27 1993-01-26 Hoffmann-La Roche Inc. Nucleotide sequences which are selectively expressed in pre-B cells and probes therefor
US4801577A (en) * 1987-02-05 1989-01-31 Syntex (U.S.A.) Inc. Nonapeptide and decapeptide analogs of LHRH useful as LHRH antagonists
US4851385A (en) * 1987-07-15 1989-07-25 Indiana University Foundation LHRH antagonist analogs having low histamine-release activity
US4800191A (en) * 1987-07-17 1989-01-24 Schally Andrew Victor LHRH antagonists
US4935491A (en) * 1987-08-24 1990-06-19 Board Of Regents, The University Of Texas System Effective antagonists of the luteinizing hormone releasing hormone which release negligible histamine
WO1989007450A1 (en) * 1988-02-10 1989-08-24 Abbott Laboratories Lhrh analogs
US5300492A (en) * 1988-02-10 1994-04-05 Tap Pharmaceuticals LHRH analogs
US5110904A (en) * 1989-08-07 1992-05-05 Abbott Laboratories Lhrh analogs
US5140009A (en) * 1988-02-10 1992-08-18 Tap Pharmaceuticals, Inc. Octapeptide LHRH antagonists
GB2218102B (en) * 1988-04-08 1992-09-16 Sandoz Ltd Calcitonin peptide derivatives
US4992421A (en) * 1988-04-19 1991-02-12 Abbott Laboratories Luteinizing hormone releasing hormone antagonist
US5258492A (en) * 1988-10-21 1993-11-02 The Administrators Of The Tulane Educational Fund LHRH analogues with cytotoxic moieties at the sixth position
US5171835A (en) * 1988-10-21 1992-12-15 The Administrators Of The Tulane Educational Fund LHRH antagonists
US5296468A (en) * 1989-10-30 1994-03-22 The Salk Institute For Biological Studies GnRH analogs
US5169932A (en) * 1989-10-30 1992-12-08 The Salk Institute For Biological Studies Gnrh analogs
US5352796A (en) * 1989-10-30 1994-10-04 The Salk Institute For Biological Studies Amino acids useful in making GnRH analogs
US5064939A (en) * 1990-02-06 1991-11-12 The Salk Institute For Biological Studies Cyclic gnrh antagonists
US5180711A (en) * 1990-06-14 1993-01-19 Applied Research Systems Ars Holding N.V. Combined treatment with gnrh antagonist and gnrh to control gonadotropin levels in mammals
CN1036343C (zh) * 1990-11-10 1997-11-05 天津市计划生育研究所 新促黄体生成素释放激素拮抗类似物的制备方法
IL101074A (en) * 1991-03-14 1997-09-30 Salk Inst For Biological Studi GnRH ANALOGS AND THEIR PREPARATION
US5340585A (en) * 1991-04-12 1994-08-23 University Of Southern California Method and formulations for use in treating benign gynecological disorders
US5516887A (en) * 1991-04-25 1996-05-14 Romano Deghenghi Luteinizing hormone releasing hormone antagonist peptides
DE4117507A1 (de) * 1991-05-24 1992-11-26 Schering Ag Verfahren zur herstellung von n(pfeil hoch)6(pfeil hoch)-substituierten lysin-derivaten
US5480969A (en) * 1992-09-15 1996-01-02 The Administrators Of The Tulane Educational Fund Antagonists of LHRH
US5371070A (en) * 1992-11-09 1994-12-06 The Salk Institute For Biological Studies Bicyclic GnRH antagonists and a method for regulating the secretion of gonadotropins
WO1994013313A1 (en) * 1992-12-04 1994-06-23 Abbott Laboratories 6-position modified decapeptide lhrh antagonists
ES2164096T3 (es) * 1992-12-18 2002-02-16 Abbott Lab Antagonistas de lhrh que comprenden restos de aminoacilo modificados en posicion 5 y 6.
SG50426A1 (en) * 1993-05-20 1998-07-20 Biotech Australia Pty Ltd Lhrh antagonists
DE4320201A1 (de) * 1993-06-18 1995-01-12 Asta Medica Ag Verwendung von Cetrorelix und weiteren Nona- und Dekapeptiden zur Herstellung eines Arzneimittels zur Bekämpfung von Aids und zur Wachstumsstimulation
US5502035A (en) * 1993-08-06 1996-03-26 Tap Holdings Inc. N-terminus modified analogs of LHRH
US5413990A (en) * 1993-08-06 1995-05-09 Tap Pharmaceuticals Inc. N-terminus modified analogs of LHRH
US5508383A (en) * 1994-03-09 1996-04-16 Tap Holdings Inc. Cyclic peptide LHRH antagonists
US5506207A (en) * 1994-03-18 1996-04-09 The Salk Institute For Biological Studies GNRH antagonists XIII
US5516759A (en) * 1994-12-08 1996-05-14 Tap Holdings Inc. LHRH antagonists having lactam groups at the N-terminus
US5843901A (en) * 1995-06-07 1998-12-01 Advanced Research & Technology Institute LHRH antagonist peptides
US5780435A (en) * 1995-12-15 1998-07-14 Praecis Pharmaceuticals Incorporated Methods for treating prostate cancer with LHRH-R antagonists

Also Published As

Publication number Publication date
US20030040482A1 (en) 2003-02-27
JP2009040793A (ja) 2009-02-26
ATE432941T1 (de) 2009-06-15
US20030181385A1 (en) 2003-09-25
EP0794961A2 (de) 1997-09-17
EP1188768A3 (de) 2002-10-23
LU91225I2 (fr) 2006-05-03
US20020115615A1 (en) 2002-08-22
JP4164125B2 (ja) 2008-10-08
PT1188768E (pt) 2009-08-13
DK1188768T3 (da) 2009-09-21
PT794961E (pt) 2003-01-31
US5843901A (en) 1998-12-01
EP0794961B1 (de) 2002-08-28
JP2007302695A (ja) 2007-11-22
JPH11507374A (ja) 1999-06-29
ES2177789T3 (es) 2002-12-16
ES2326861T3 (es) 2009-10-21
LU91857I2 (fr) 2011-10-24
EP1188768A2 (de) 2002-03-20
HK1045161A1 (en) 2002-11-15
DK0794961T3 (da) 2002-10-21
DE69623254T2 (de) 2002-12-19
US7071165B2 (en) 2006-07-04
HK1045161B (zh) 2009-12-24
AU715399B2 (en) 2000-02-03
CA2219460C (en) 2009-04-14
DE69623254D1 (de) 2002-10-02
WO1996040757A2 (en) 1996-12-19
EP1188768B1 (de) 2009-06-03
WO1996040757A3 (en) 1997-02-20
DE122006000012I2 (de) 2010-02-04
AU6168096A (en) 1996-12-30
CA2219460A1 (en) 1996-12-19
US6423686B1 (en) 2002-07-23
DE69535963D1 (de) 2009-07-16
ATE222924T1 (de) 2002-09-15

Similar Documents

Publication Publication Date Title
DE122006000012I1 (de) Lhrh antagonistische Peptide
ES2103857T3 (es) Peptidos ciclicos y su uso.
PT1288223E (pt) Derivados de peptidos terapeuticos
DK0966297T4 (da) Regulering af gastrointestinal motilitet
SE8903042L (sv) Pharmaceutical compositions comprising cyklosporins
LV10720A (lv) Peptidi un farmaceitiska kompozicija uz to bazes
DE69801369T2 (de) Peptidanaloge des lh-rh, ihre verwendungen und die sie enthaltenden pharmazeutischen zusammensetzungen
ATE196296T1 (de) Dolastatin analog
DE60044945D1 (de) Auf scf peptid basiertes basolaterales sortiersignal und inhibitoren dafür
NZ231636A (en) Anticoagulant peptides analogus to hirudins' active site
BR9714376A (pt) Antagonistas de somatostatina
ATE46347T1 (de) Immunostimulierende peptide.
FR2717390B1 (fr) Compositions thérapeutiques à base de peptides capables d'inhiber la libération de pepsine.
IT8720701A0 (it) Composizioni farmaceutiche adattivita' immunomodulante.
IT8719949A0 (it) Composizioni farmaceutiche adattivita' immunomodulante.
FI991120A0 (fi) Vesiliukoisten peptidien pitkäaikaisesti vapautuvat koostumukset
TH17650EX (th) "อนุพันธ์เปปไทด์ที่ใช้รักษาโรค"(therapeutic peptide derivatives)
IT8847610A0 (it) Composizioni farmaceutiche adattivita' antiprolattinica
IT8622051A0 (it) Composizioni farmaceutiche adattivita' cicatrizzante.
IT8820026A0 (it) Composizioni farmaceutiche adattivita' antineoplastica.